Fertility Issues Clinical Trial
— P4ROfficial title:
Rescue Progesterone Supplementation in Patients With Low Progesterone on the Day of Embryo Transfer for Artificial Endometrial Preparation Cycles: a Non-inferiority Study
Verified date | January 2024 |
Source | Clinique Ovo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Endometrin is a progesterone supplement prescribed during in vitro fertilization (IVF) for preparation for embryo transfer. The usual dose of Endometrin is 100 mg two to three times per day in the form of an effervescent tablet to be inserted vaginally. The purpose of this research project is to evaluate the dose response of the Endometrin when determined based on the blood level of progesterone on the day of the FET. According to the literature, a predefined level of progesterone in the blood should be reached in order to have favorable conditions for pregnancy. The hypothesis being that a woman with low progesterone levels would benefit from a dose of Endometrin of 600 mg (200 mg 3x/day) to decrease the risk of miscarriage and improve the chances of pregnancy. Women with adequate progesterone levels according to the literature, would continue with the standard dose of progesterone prescribed at clinique ovo which is 300 mg (100 mg 3x/day). PIBF (Progesterone Induced Blocking Factor) levels, a protein found in the blood that could also predict pregnancy outcomes in women using IVF will also be looked at.
Status | Active, not recruiting |
Enrollment | 150 |
Est. completion date | June 30, 2026 |
Est. primary completion date | September 30, 2025 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 42 Years |
Eligibility | Inclusion Criteria: - Women 18-42 years of age - Normal uterine cavity (according to treating physician) - FET substituted cycle prescribed - First or second cycle of FET - Adequate endometrial pattern (triple layer) and thickness (>7 mm) after adequate standard endometrial preparation in artificial cycle Exclusion Criteria: - Any uterine abnormalities confirmed by treating physician making participant unable to proceed with FET - Patients with personalized FET according to the endometrial receptivity assay tests - Previous allergic reactions to progesterone or any of the ingredients of Endometrin - Severe hepatic dysfunction or disease - Known or suspected breast cancer or genital tract cancer - Known active arterial or venous thromboembolism or severe thrombophlebitis or cerebro-vascular disease, or a history of these events - Diagnosed porphyria - Undiagnosed abnormal vaginal bleeding - Known missed abortion or ectopic pregnancy - Recurrent pregnancy loss excluding biochemical pregnancies - Hypersensitivity to Acetylsalicylic acid (ASA), salicylates, non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, antipyretics or other ingredients in the product or component of the container - Acute gastrointestinal ulcer, history of gastrointestinal ulcers and hemorrhagic diathesis - Active or severe renal disease, or congestive heart failure - History of asthma induced by salicylates or other NSAIDs - Use of methotrexate at doses of 15mg/week or more - Glucose-6-phosphate dehydrogenase (G6PD) deficiency |
Country | Name | City | State |
---|---|---|---|
Canada | Clinique Ovo | Montreal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Clinique Ovo | Ferring Pharmaceuticals |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Blood test to evaluate the prevalence of PIBF | Progesterone Inducing Blocking Factor (PIBF) has been found to to have an important part in creating a welcoming environment for the embryo | Before embryo transfer and 10 days after embryo transfer | |
Primary | Evaluate the ongoing pregnancy rate | Viability ultrasound | 6 to 8 weeks after Frozen Embryo Transfer | |
Secondary | Evaluate the miscarriage rate | Viability ultrasound | 6 to 8 weeks after Frozen Embryo Transfer | |
Secondary | Evaluate progesterone levels | Progesterone levels will be tested at two different times | Before embryo transfer and 10 days after embryo transfer | |
Secondary | Evaluate the rate of biochemical pregnancy | Serum pregnancy test to measure Beta Human Chorionic Gonadotropin (BhCG) levels | 10 days after frozen embryo transfer |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06387498 -
Testicular Tissue Cryopreservation (TTC)
|
N/A | |
Recruiting |
NCT04519593 -
ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma
|
N/A | |
Recruiting |
NCT05980091 -
Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration.
|
Phase 1 | |
Recruiting |
NCT06043609 -
Outcome Evaluation After Fertility Preservation
|
||
Not yet recruiting |
NCT05048771 -
Fertility and Temporality in Pediatric Oncology
|
||
Completed |
NCT05368194 -
Food Intake and Epigenetic Alteration in the Spermatozoa of Singletons and Twins
|
N/A | |
Recruiting |
NCT05176535 -
Determination of Vaginal Colonization and the Effect of an Oral Probiotic (PROSALVAG)
|
N/A | |
Recruiting |
NCT06360471 -
Fertility Preservation and Pregnancy and Offspring Health Outcomes in Female Cancer
|
||
Recruiting |
NCT05271981 -
Fertility After Uterine Artery Embolization
|
||
Recruiting |
NCT05815719 -
Continuous Double Ovarian Stimulation.
|
Phase 4 | |
Recruiting |
NCT06127875 -
Effects of Trying to Conceive Using an Home- or Hospital-based Ovulation Monitoring on Stress
|
||
Recruiting |
NCT05658848 -
Effect of Collaborative Infertility Counseling on Coping Strategies and Marital Satisfaction
|
N/A | |
Not yet recruiting |
NCT05385848 -
Autologous Platelet-rich Plasma (PRP) Infusion to Improve Outcomes in Women With Ovarian Insufficiency: a Pilot Study
|
N/A | |
Completed |
NCT04396210 -
Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic
|
||
Completed |
NCT05134090 -
Percutaneous Laparoscopy for Ovarian Tissue Cryopreservation.
|
||
Completed |
NCT05905289 -
Survival and Reproductive Outcomes of Malignant Ovarian Germ Cell Tumors
|
||
Recruiting |
NCT05316467 -
Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
|
Phase 2/Phase 3 | |
Completed |
NCT04600869 -
Effects of Naturalistic Decision-Making Model-based Oncofertility Care Education
|
N/A | |
Withdrawn |
NCT04683237 -
Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06179420 -
The Effectiveness of Advanced Decision Support Tool (OPT-IVF) for IVF Treatment
|